Table of Content

1 INTRODUCTION
1.1 Study Assumptions & Market Defination
1.2 Scope of the Study


2 RESEARCH METHODOLOGY


3 EXECUTIVE SUMMARY


4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Stem Cell therapy for Lower Back Pain
4.2.2 Increasing Prevelence of Nerve Pain Disorders
4.2.3 Growing geriatric population
4.3 Market Restraints
4.3.1 Side Effects of Treatments and Availability of Counterfeit Drugs
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry


5 MARKET SEGMENTATION (Market Size by Value - USD million)
5.1 By Pain Type
5.1.1 Acute Pain
5.1.2 Subacute Low Back Pain
5.1.3 Chronic Back Pain
5.1.4 Other Pain Types (Mechanical pain, Radicular pain, Radiculitis)
5.2 By Diagnosis
5.2.1 Assessment of Pain
5.2.2 Clinical History
5.2.3 Physical Examination
5.2.4 Imaging Guidelines
5.3 By End-User
5.3.1 Hospitals
5.3.2 Orthopedic Clinics
5.3.3 Other End -Users
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle-East and Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle-East and Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America


6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Johnson & Johnson Services Inc.
6.1.2 Pfizer Inc
6.1.3 Vertebral Technologies, Inc.
6.1.4 Merck & Co.
6.1.5 Medtronic
6.1.6 Boston Scientific Corporation
6.1.7 Mesoblast Limited
6.1.8 SpineThera
6.1.9 Stayble Therapeutics
6.1.10 Eli Lilly and Company
6.1.11 Persica Pharmaceuticals


7 MARKET OPPORTUNITIES AND FUTURE TRENDS